Warning: The NCBI web site requires JavaScript to function. more...
An official website of the United States government
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.
HOXB13 epigenome in castration-resistant prostate cancer
PubMed Full text in PMC Similar studies SRA Run Selector
HOXB13 lysine 13 acetylation regulated transcriptional targets in castration-resistant prostate cancer
PubMed Full text in PMC Similar studies Analyze with GEO2RSRA Run Selector
Targeted Escalation of Acetylated HOXB13 Regulated Super-Enhancers Promotes Prostate Tumor Autonomy
PubMed Full text in PMC Similar studies
Targeted Escalation of an Acetylated HOXB13-dependent Tyrosine Kinase Super-Enhancer Network Promotes Prostate Tumor Autonomy
Targeted Escalation of Tyrosine Kinase Super-Enhancer Network Engineered by Acetylated HOXB13 Spurs Prostate Tumor Autonomy
Diverse AR-V7 cistromes in castration-resistant prostate cancer are governed by HoxB13
Chronologically Modified Androgen Receptor in Recurrent Castration Resistant Prostate Cancer and its therapeutic targeting
Identification of HOXB13 target genes responsive to BET inhibitors
Gene Expression Analysis of metastatic CRPC cell line C4-2B treated with the dual BET-kinase inhibitor MA4-022-1
Targeting the fibroblast growth factor pathway in molecular subtypes of castration-resistant prostate cancer
PubMed Similar studies Analyze with GEO2R
Expression data from LNCaP cells treated with DHT and enzalutamide
Newly developed preclinical models reveal broad spectrum CDK inhibitors as potent drugs for CRPC exhibiting primary resistance to enzalutamide
PubMed Full text in PMC Similar studies Analyze with GEO2R
Profiles of prostate cancer cell lines
Cellular androgen content influences enzalutamide agonism of F877L mutant androgen receptor
ROR-γ drives androgen-receptor expression and represents a therapeutic target in castration-resistant prostate cancer
Transcriptome analysis of VCaP xenografts resistant to dual therapy with abiraterone and enzalutamide
Activation of P-TEFb by androgen receptor-regulated enhancer RNAs in androgen deprivation conditions [ChIP-Seq]
Activation of P-TEFb by enhancer RNAs associated with lethal prostate cancer [ChIP-seq]
Activation of the P-TEFb Complex by Lethal Prostate Cancer-Associated Enhancer RNAs
Filters: Manage Filters
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on